The five-year survival rate for people diagnosed with the most advanced stage of non-small cell lung cancer (NSCLC) is pretty grim, only between one and 10 percent. To address this devastating condition, the Board of the California Institute for Regenerative Medicine (CIRM) today voted to invest almost $12 million in a team from UCLA that … Continue reading CIRM invests in stem cell clinical trial targeting lung cancer and promising research into osteoporosis and incontinence
ICOC Board Meetings
Budget for CIRM’s Future
The CIRM Board discusses the future of the Stem Cell Agency Last week the California Institute for Regenerative Medicine's looked at what the stem cell agency has in the back, and set out a plan to budget for CIRM's future. Last year CIRM spent about $306 million on a wide range of research. That leaves … Continue reading Budget for CIRM’s Future